Intranasal and sublingual delivery of inactivated polio vaccine
- PMID: 28400164
- DOI: 10.1016/j.vaccine.2017.03.090
Intranasal and sublingual delivery of inactivated polio vaccine
Abstract
Polio is on the brink of eradication. Improved inactivated polio vaccines (IPV) are needed towards complete eradication and for the use in the period thereafter. Vaccination via mucosal surfaces has important potential advantages over intramuscular injection using conventional needle and syringe, the currently used delivery method for IPV. One of them is the ability to induce both serum and mucosal immune responses: the latter may provide protection at the port of virus entry. The current study evaluated the possibilities of polio vaccination via mucosal surfaces using IPV based on attenuated Sabin strains. Mice received three immunizations with trivalent sIPV via intramuscular injection, or via the intranasal or sublingual route. The need of an adjuvant for the mucosal routes was investigated as well, by testing sIPV in combination with the mucosal adjuvant cholera toxin. Both intranasal and sublingual sIPV immunization induced systemic polio-specific serum IgG in mice that were functional as measured by poliovirus neutralization. Intranasal administration of sIPV plus adjuvant induced significant higher systemic poliovirus type 3 neutralizing antibody titers than sIPV delivered via the intramuscular route. Moreover, mucosal sIPV delivery elicited polio-specific IgA titers at different mucosal sites (IgA in saliva, fecal extracts and intestinal tissue) and IgA-producing B-cells in the spleen, where conventional intramuscular vaccination was unable to do so. However, it is likely that a mucosal adjuvant is required for sublingual vaccination. Further research on polio vaccination via sublingual mucosal route should include the search for safe and effective adjuvants, and the development of novel oral dosage forms that improve antigen uptake by oral mucosa, thereby increasing vaccine immunogenicity. This study indicates that both the intranasal and sublingual routes might be valuable approaches for use in routine vaccination or outbreak control in the period after complete OPV cessation and post-polio eradication.
Keywords: Adjuvant; Inactivated polio vaccine; Intranasal; Mucosal delivery; Sublingual; Vaccines.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576132 Free PMC article. Review.
-
Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.Hum Vaccin Immunother. 2014;10(12):3611-21. doi: 10.4161/hv.32253. Hum Vaccin Immunother. 2014. PMID: 25483682 Free PMC article.
-
The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.Vaccine. 2015 Apr 15;33(16):1909-15. doi: 10.1016/j.vaccine.2015.02.069. Epub 2015 Mar 9. Vaccine. 2015. PMID: 25765967
-
Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.Vaccine. 2014 Apr 25;32(20):2382-8. doi: 10.1016/j.vaccine.2013.12.043. Epub 2014 Jan 13. Vaccine. 2014. PMID: 24434044
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
-
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576132 Free PMC article. Review.
-
Development of Nasal Vaccines and the Associated Challenges.Pharmaceutics. 2022 Sep 20;14(10):1983. doi: 10.3390/pharmaceutics14101983. Pharmaceutics. 2022. PMID: 36297419 Free PMC article. Review.
-
Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.Adv Healthc Mater. 2019 Feb;8(4):e1801180. doi: 10.1002/adhm.201801180. Epub 2018 Dec 10. Adv Healthc Mater. 2019. PMID: 30537400 Free PMC article. Review.
-
Noninvasive vaccination against infectious diseases.Hum Vaccin Immunother. 2018 Jul 3;14(7):1717-1733. doi: 10.1080/21645515.2018.1461296. Epub 2018 May 17. Hum Vaccin Immunother. 2018. PMID: 29624470 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
